[ad_1]
Vilnius University (VU) Professor of Infectious Diseases Arvydas Ambrozaitis emphasizes that during the third phase of AstraZeneca’s clinical trials, this vaccine was not found to cause serious health problems, disease exacerbations or deaths, and all deaths were not related to the vaccine.
Remember that the vaccine was developed using a non-human adenovirus with an inserted coronavirus protein gene; When the drug enters human muscle cells, the genetic material gives the adenovirus the command to produce the coronavirus needle protein. This protein remains in the muscles, and in response, the human body begins to produce protective antibodies against the protein.
“It just came to our knowledge then. At this point, as a vaccine expert, I can safely say that this vaccine, like others, cannot cause any thromboembolic disease, let alone death. This is impossible,” said the expert.
This vaccine, like others, cannot cause any thromboembolic disease, especially death.
He stressed that the vaccine did not contain “any ingredient, a substance that could affect the vital functions of the human being, especially the risk of disease, thromboembolism or myocardial infarction.”
Denmark, Norway and Iceland temporarily stopped receiving the AstraZeneca vaccine this week after noticing blood clots in some people after the vaccine. Experts emphasize that the decision is preventive, since a causal link between the vaccine and these disorders has not yet been established.
Austria, Latvia, Lithuania and Luxembourg suspended vaccination with one batch of vaccine, following reports from Austria that a 49-year-old nurse had died from increased blood clotting after vaccination and another woman had suffered a pulmonary embolism. The European Medicines Agency (EMA) has already ruled out that this could be related to the vaccine.
In total, as of March 9, the EVA had received 22 reports of blood clots in vaccinated people.
A. Ambrozaitis highlights that the vaccination has been temporarily suspended, he is convinced that the EEA experts will confirm that the reactions are not related to the vaccine and will continue to use.
“You see – it will definitely be announced after that that the cases are not related. But it is important that this be examined, because we cannot know everything to the fullest (…). There are many people who have comorbidities with a greater tendency to thrombosis There is no need for vaccines: our diet is bad, we are overweight, we have high cholesterol and many other reasons for our lifestyle, “he said.
No vaccine is needed: our diet is bad, we are overweight, high cholesterol, many other reasons for our lifestyle.
“I would say that the use must be renewed, because this vaccine is approved by the European Medicines Agency, and it is in charge of registering each vaccine, it is signed by those responsible, it is authorized in the European Union. Authorization will be granted only if the vaccine is sufficiently safe, effective and meets the standards of good clinical practice. All three vaccines are in use, and now a fourth, Johnson & Johnson, agrees with that, ”said the expert.
Professor Aurelija Žvirblienė, an immunologist at the VU Life Sciences Center, highlights that, according to official data, after the EU vaccinated 5 million, some 30 cases of human embolism have been reported.
Photo by Lukas Balandis / 15min / Aurelija Žvirblienė
“The same frequency of these embolism cases is only among unvaccinated people. But I don’t have the data that the experts analyzed by the European Medicines Agency have. First of all, you should be guided by what your experts recommend. There were more cases, we have to analyze them, in the end, and the manufacturer has to say a word, ”A. Žvirblienė told BNS.
“Given the data that I have available to the public, I do not see any reason why the vaccination should be stopped. But, on the other hand, it takes time, to find out all the things,” he added.
Currently, three COVID-19 vaccines approved by the European Medicines Agency are used in Lithuania: Pfizer and BioNTech, Moderna and AstraZeneca. The Johnson & Johnson vaccine is being prepared for use by EVA on Thursday.
If you have any questions about the COVID-19 vaccine, please send them to our editorial staff by email. email address [email protected]
[ad_2]
